Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial

Seven patients, four women and three men, with a median age of 64 years (range, 53-74 years) were randomized to treatment with either ketanserin, 40-160 mg daily, or placebo. The study included 13 treatment periods with ketanserin and 13 with placebo. All patients had typical symptoms, with flushing...

Full description

Saved in:
Bibliographic Details
Published inScandinavian journal of gastroenterology Vol. 21; no. 7; p. 816
Main Authors Gustafsen, J, Lendorf, A, Raskov, H, Boesby, S
Format Journal Article
LanguageEnglish
Published England 01.01.1986
Subjects
Aged
Carcinoid Tumor - drug therapy
Clinical Trials as Topic
Double-Blind Method
Female
Humans
Ketanserin - therapeutic use
Male
Middle Aged
Random Allocation
Serotonin Antagonists - therapeutic use
Online AccessGet more information

Cover

More Information
Summary:Seven patients, four women and three men, with a median age of 64 years (range, 53-74 years) were randomized to treatment with either ketanserin, 40-160 mg daily, or placebo. The study included 13 treatment periods with ketanserin and 13 with placebo. All patients had typical symptoms, with flushing as their main complaint. The diagnosis had been verified histologically. All had elevated excretion of 5-hydroxy-3-indoleacetic acid in urine. During the trial ketanserin reduced the number of flushing attacks in five patients (p less than 0.05). Diarrhoea was reduced in two patients. No side effects were observed. Ketanserin seems valuable for the symptomatic relief in the carcinoid syndrome.
ISSN:0036-5521
1502-7708
DOI:10.3109/00365528609011123